Seres Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Seres Therapeutics, Inc. (MCRB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $98.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-03-12
- Seres Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $98.00K.
- Seres Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Seres Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $438.00K, a 55.35% decline from fiscal 2022.
- Seres Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $981.00K, a 79.25% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|
| 2025-12-31 | $98.00K 10-K · filed 2026-03-12 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-12 |
| 2023-12-31 | $438.00K 10-K · filed 2026-03-12 |
| 2022-12-31 | $981.00K 10-K · filed 2025-03-13 |
| 2021-12-31 | $4.73M 10-K · filed 2024-03-05 |
| 2020-12-31 | $37.26M 10-K · filed 2023-03-07 |
| 2019-12-31 | $244.00K 10-K · filed 2022-03-01 |
| 2018-12-31 | $1.80M 10-K · filed 2021-03-02 |
| 2017-12-31 | $1.91M 10-K · filed 2020-03-02 |
| 2016-12-31 | $34.87M 10-K · filed 2019-03-06 |
| 2015-12-31 | $4.13M 10-K · filed 2018-03-08 |
| 2014-12-31 | $512.00K 10-K · filed 2017-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |